PDCD1 and glioblastoma: The combined administration of neutrophil‐backpacks and anti‐PD‐1 antibody induced T cell‐mediated anti‐tumor immune responses systemically and significantly augmented the therapeutic efficacy of the anti‐PD‐1 antibody in an orthotopically GL261 GBM model.